Opinion

Video

Study Design: Comparing the ARCHES and ARANOTE trials

A panelist discusses how the ARCHES and ARANOTE trials differ in their fundamental design elements, with ARCHES evaluating enzalutamide plus androgen deprivation therapy (ADT) vs placebo plus ADT in both metastatic and nonmetastatic patients, whereas ARANOTE specifically studied apalutamide plus ADT vs ADT alone in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.

Summary for Physicians: Limitations of MAIC Analyses

Summary for Physicians: ARCHES vs. ARANOTE Trial Designs

The ARCHES and ARANOTE trials differ substantially in their fundamental design elements:

ARCHES Trial:

  • Evaluated enzalutamide plus ADT vs placebo plus ADT
  • Included both metastatic and nonmetastatic patient populations

ARANOTE Trial:

  • Evaluated apalutamide plus ADT vs ADT alone
  • Specifically focused on patients with newly diagnosed metastatic hormone-sensitive prostate cancer only

These design differences should be considered when interpreting and comparing results between these 2 androgen receptor pathway inhibitor trials.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.